CRF announces TCT 2024 late-breaking clinical trials and science
Annual Scientific Symposium will take place October 27-30 in Washington, D.C.
2024-08-27
(Press-News.org) NEW YORK – August 27, 2024 – The Cardiovascular Research Foundation® (CRF®) is pleased to announce the late-breaking clinical trials and science to be featured at TCT® 2024. As the annual scientific symposium of CRF® and the world’s premier educational meeting specializing in interventional cardiovascular medicine, TCT® 2024 will be held October 27-30 in Washington, D.C. at the Walter E. Washington Convention Center.
For over three decades, TCT® has been at the forefront of innovation, education, and collaboration in interventional cardiology, with a steadfast commitment to improving the survival and quality of life for patients suffering from heart and vascular disease. Every year, TCT® features groundbreaking research that directly impacts patient care and how physicians treat heart disease.
In the rapidly evolving field of medicine, late-breaking trials are highly anticipated and offer clinicians the opportunity to learn about new interventions, drugs, techniques, and strategies that could potentially improve patient outcomes. The 25 studies selected for presentation at TCT® examine the safety and effectiveness of minimally invasive techniques, pharmaceuticals, technologies, and devices that demonstrate potential to treat or prevent cardiovascular disease. Late-breaking trials will be presented during the main sessions and highlighted during press conferences scheduled for Monday, October 28, Tuesday, October 29, and Wednesday, October 30.
Monday, October 28, 2024
EARLY TAVR: Transcatheter Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis: Results of the EARLY TAVR Trial
EVOLVED: Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Left Ventricular Myocardial Fibrosis
TAVR UNLOAD: Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis
DCB-BIF: Comparison of Noncompliant Balloon With Drug-Coated Balloon Angioplasty for Side Branch Stenosis After Provisional Stenting for Patients With True Coronary Bifurcation Lesions
HELP PCI: Early Administration of Heparin at First Medical Contact Versus in the Cath Lab for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: A Multicenter, Randomized Trial
DRAMI: Randomized Comparison of Puncture Success Rate Between Distal Radial Access and Transradial Access in Patients With ST-Elevation Myocardial Infarction
INFINITY-SWEDEHEART Complex PCI: 1-Year and Landmark 6–12 Month Clinical Outcomes Among Patients With Complex Lesion Subsets Treated with DynamX Bioadaptor Compared to a Contemporary Drug Eluting Stent
CONFIRM-2: Artificial Intelligence Enabled Quantitative CT Assessment of Atherosclerosis and Major Adverse Events: A Multi-Center International Registry
Tuesday, October 29, 2024
ECLIPSE: A Large-Scale, Randomized Trial of Orbital Atherectomy vs. Conventional Balloon Angioplasty in Severely Calcified Coronary Arteries Prior to DES Implantation
CLEAR SYNERGY (OASIS 9): A 2x2 Factorial Randomized Controlled Trial of Colchicine Versus Placebo and Spironolactone Versus Placebo in Patients With Myocardial Infarction: Results of the Colchicine Factorial
PEERLESS: Large-Bore Mechanical Thrombectomy vs Catheter-Directed Thrombolysis for Treatment of Intermediate-Risk Pulmonary Embolism
SIRONA: Head-to-Head Comparison of Sirolimus- Versus Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Artery
Co-STAR: Colchicine in Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement: A Double-Blind Randomized Controlled Trial
ACCESS TAVI: Randomized Comparison of Strategies for Vascular Access Closure After Transcatheter Aortic Valve Implantation
PROTECTED TAVR: US Subgroup: Cerebral Embolic Protection in the US Cohort of the PROTECTED TAVR Randomized Trial
RHEIA/PARTNER Pooled Analysis in Women: Transcatheter vs. Surgical Aortic Valve Replacement in Women: A Pooled Analysis of the RHEIA and PARTNER 3 Trials
ALIGN-AR 2 Year: Two-Year Outcomes of Transcatheter Aortic Valve Replacement With JenaValve Trilogy™ in High Surgical Risk Patients With Moderate-to-Severe or Severe Native Aortic Regurgitation
Wednesday, October 30, 2024
TRISCEND II: Randomized Comparison of Transcatheter Valve Replacement vs. Optimal Medical Therapy for Severe Tricuspid Regurgitation
FAVOR III Europe: Quantitative Flow Ratio or Fractional Flow Reserve for Guiding Coronary Revascularization
FLASH: Artificial Intelligence-Based Fully Automated Quantitative Coronary Angiography Versus Optical Coherence Tomography Guidance for Coronary Stent Implantation: A Multicenter, Randomized Controlled Non-Inferiority Trial
TARGET IV: International Multicenter Randomized Assessment of the Firehawk® Rapamycin Eluting Coronary Stent System
TARGET DAPT: Prospective, Multicenter, Open-Label, Randomized Controlled Trial of 3-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of the Biodegradable Polymer Firehawk® Sirolimus-Eluting Coronary Stent
CLEAR-IE: Outcomes of Percutaneous Mechanical Aspiration in Right-Sided Infective Endocarditis: A Multicenter Registry
CLASP IID 2 Year RCT and Registry: Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation
MATTERHORN: Atrial MR Subgroup Transcatheter Repair Versus Surgery in Atrial Mitral Regurgitation: Results From the MATTERHORN Trial
Media are invited to attend TCT® and can apply for media credentials at: https://tct2024.crfconferences.com/press-registration.
Receive updates on X at https://x.com/TCTConference and https://x.com/crfheart.
About CRF® and TCT®
The Cardiovascular Research Foundation® (CRF®) is a global leader in interventional cardiovascular medicine, driving innovation, spearheading groundbreaking research, and transforming education in the field. Through its relentless pursuit of excellence, CRF® not only accelerates medical breakthroughs but also equips healthcare professionals with the tools and knowledge necessary to enhance survival rates and elevate the quality of life for millions worldwide. CRF’s centers of excellence include the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD, and Structural Heart: The Journal of the Heart Team.
Transcatheter Cardiovascular Therapeutics® (TCT®) is the annual scientific symposium of CRF® and the world’s premier educational meeting specializing in interventional cardiovascular medicine. Anchored in a legacy spanning over three decades, TCT® is a world-class educational experience featuring disruptive innovation, scientific breakthroughs, expert-led tutorials, hands-on training, and ample opportunities for networking and collaboration.
For more information, visit www.crf.org and www.tctconference.com.
###
END
ELSE PRESS RELEASES FROM THIS DATE:
2024-08-27
BINGHAMTON, N.Y. -- More companies are embracing remote work, and with that comes a need for more frequent communication. Teamwork through a screen isn’t always the same as having a group in the same room, so how are companies cultivating leaders in these virtual settings?
New research involving a collaboration between Binghamton University, State University of New York schools and research centers shows how, in virtual teams where nonverbal cues are limited, a person’s engagement and influence in conversations can significantly shape whether they’re perceived as a leader.
But taking charge of the conversation isn’t enough, the study found; for leadership ...
2024-08-27
Smoking harms almost every part of your body. But if you smoke when pregnant, the toxic chemicals in tobacco will also harm your unborn baby, with new research showing that it could lead to reduced academic outcomes at school.
In a systematic review of 19 studies and 1.25 million participants, researchers at the University of South Australia along with a team at Curtin University, SAHMRI, Harvard University and others* found that 79% of studies reported reduced academic achievement in children exposed to maternal prenatal smoking.
An additional meta-analysis of eight primary studies with 723,877 participants ...
2024-08-27
Researchers from Wake Forest University and University of California-Riverside published a new Journal of Marketing article that examines the dynamic BMR retail context and investigates the sales incentives there.
The study, forthcoming in the Journal of Marketing, is titled “Group or Individual Sales Incentives? What is Best for Brand-Managed Retail Sales Operations?” and is authored by Wenshu Zhang, Jia Li, and Subramanian Balachander.
Should a brand adopt group or individual sales incentives for its retail sales force? Could differences in brand strength or brand equity affect how brands incentivize their sales ...
2024-08-27
Shortly after Kelly Cervantes’ daughter Adelaide was born, she started having terrible seizures. Doctors were unable to give her a solution, or even a cause.
“We never had an overarching diagnosis for her, which was extraordinarily frustrating and isolating,” she says. “If we did, we could join groups or talk to people who had various symptoms in common. We also had no idea what her prognosis looked like, or if we could have other children.”
Over time her condition worsened and sadly she died five days before her fourth birthday.
“She ...
2024-08-27
SAN ANTONIO, Aug. 27, 2024 – Kenneth M. Hargreaves, DDS, PhD, professor of endodontics at the School of Dentistry of The University of Texas Health Science Center at San Antonio (UT Health San Antonio), has been named inaugural director of the school’s Center for Pain Therapeutics and Addiction Research.
Hargreaves, who chaired the Department of Endodontics at the school for 26 years, is a world-renowned expert in pain research and has served as principal or co-principal investigator on numerous National Institutes of Health, Department of Defense and foundation-funded projects totaling more than $139 million.
Just recently, his research proposal, ...
2024-08-27
Researchers at the University of Notre Dame have developed a novel, automated device capable of diagnosing glioblastoma, a fast-growing and incurable brain cancer, in less than an hour. The average glioblastoma patient survives 12-18 months after diagnosis.
The crux of the diagnostic is a biochip that uses electrokinetic technology to detect biomarkers, or active Epidermal Growth Factor Receptors (EGFRs), which are overexpressed in certain cancers such as glioblastoma and found in extracellular vesicles.
“Extracellular vesicles or exosomes are unique ...
2024-08-27
Researchers at the U.S. Department of Energy’s National Renewable Energy Laboratory (NREL) see a realistic path forward to the manufacture of bio-derivable wind blades that can be chemically recycled and the components reused, ending the practice of old blades winding up in landfills at the end of their useful life.
The findings are published in the new issue of the journal Science. The new resin, which is made of materials produced using bio-derivable resources, performs on par with the current industry standard of blades made from a thermoset resin and outperforms certain thermoplastic resins intended to be recyclable.
The researchers built a prototype 9-meter blade to ...
2024-08-27
Atomic resolution of the broad-spectrum antiviral drug cascade to facilitate the design of antiviral drugs
In your coverage, please use this URL to provide access to the freely available paper in PLOS Biology: http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3002743
Article Title: The activation cascade of the broad-spectrum antiviral bemnifosbuvir characterized at atomic resolution
Author Countries: France, United States, Germany
Funding: see manuscript END ...
2024-08-27
One in every three FDA-approved drugs targets a single superfamily of receptors dotting the surfaces of human cells. From beta blockers to antihistamines, these essential, life-saving medications trigger winding biochemical pathways, via these receptors, to ultimately prevent a heart attack, or stop an allergic reaction in its tracks.
But scientists have learned that their story is much more complicated than initially believed—a number of these drugs are in fact targeting a complex composed of one receptor and one associated protein. Now, a ...
2024-08-27
COLUMBUS, Ohio – Not all communities in the United States face the same risks for environmental problems such as air pollution, noise and wastewater. But how can federal agencies fairly identify which areas deserve the most help?
A new consensus study report from the National Academies of Sciences, Engineering and Medicine (NASEM) offer recommendations for developing tools that can help answer that question.
“Our job was to create methods to identify disadvantaged communities that most need federal resources to address environmental justice issues,” said Harvey Miller, ...
LAST 30 PRESS RELEASES:
[Press-News.org] CRF announces TCT 2024 late-breaking clinical trials and science
Annual Scientific Symposium will take place October 27-30 in Washington, D.C.
